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ship function for each individual (Mean survivorship).
Adjusted LOS at quartiles of % discharged for each func-
tion was compared with unadjusted LOS using Kaplan-
Meier method. RESULTS: Hospital unit type at random-
ization and number of comorbidities both differed signif-
icantly between groups and significantly affected LOS.
With covariate controls in the log-logistic model, line-
zolid treatment significantly reduced LOS (p  .04). Ad-
justed/unadjusted LOS at quartiles of % discharged were:
CONCLUSIONS: When adjusted for covariate differ-
ences, median LOS for linezolid patients was at least 2
days shorter than for vancomycin patients. Other differ-
ences in the LOS distribution are evident and may be im-
portant to decision-makers but off-median estimates may
be sensitive to the adjustment method used. Method-
ologic considerations are explored further.
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BACKGROUND: Several studies have demonstrated the
negative impact of chronic hepatitis C (CHC) and respec-
tive treatments on patient health-related quality of life.
Studies suggest PEGASYS provides an improved sus-
tained virological response compared with interferon (IFN)
monotherapy (30–39% vs 10–19%) and may provide
safety, quality of life (QoL), and work productivity bene-
fits compared with standard interferon/ribavirin (IFN/RBV,
REBETRONTM) combination therapy. OBJECTIVE: To
compare the safety and tolerability of treatment with PE-
GASYS vs REBETRON in previously untreated patients
with chronic hepatitis C (CHC). METHODS: A 72-week,
multicenter study randomized 412 patients to PEGASYS
180 g qw or REBETRON (IFN-26 3 MIU tiw  RBU
1000-1200 mg qd). Tolerability was assessed by the Hep-
atitis Quality of Life Questionnaire (HQLQ, assessed at
weeks 4, 12, 24, 48, 60, and 72; SF-36 plus 4 Hepatitis-
specific domains) and the Work Productivity and Activity
Impairment (WPAI) instrument. RESULTS: After 12
%
discharged
Adjusted LOS (days) Unadjusted
LOS
Individual 
correction
Mean 
survivorship Kaplan-Meier
LZD VAN LZD VAN LZD VAN
25 6 10 6 9 6 8
50 (median) 14 16 13 16 14 15
75 26 28 28 29 29 29
weeks of treatment, HCV-RNA was negative in 46.8%
of PEGASYS and 50.3% of REBETRON patients. Pa-
tients on PEGASYS showed a clinically significant differ-
ence compared to REBETRON in several AEs: anemia
(2.0% vs 32.4%), dyspnea (9.5% vs 18.1%), pruritus
(6.7% vs 17.5%). At weeks 4 and 12, patients on PEGA-
SYS compared to REBETRON had significantly better
work productivity (Estimated Wkly Work Productivity
Lost: $32.10, PEGASYS; $86.60, REBETRON) in 7 of 7
domains. Week 4 and 12 HQLQ assessments indicated
patients on PEGASYS vs those on REBETRON had clini-
cally and statistically better QoL scores in 8 of 8 SF-36
domains, both physical and mental summary scores, and
4 CHC-specific domains (P  0.05). CONCLUSIONS: The
12-week data demonstrate that patients treated with PE-
GASYS had a superior tolerance to therapy, were more
productive as measured by the WPAI, and had better
health related quality of life profiles compared with pa-
tients treated with REBETRON, while maintaining simi-
lar virological response.
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OBJECTIVE: The North Carolina Cooperative Agree-
ment (NCCoOp) for AIDS Intervention Research imple-
mented an AIDS intervention in an urban, high-risk, pri-
marily African-American, crack and injection drug-using
population. Estimated costs for the standard intervention
are $242 per person. How many future AIDS cases will
be averted by making this expenditure? METHODS: We
constructed an epidemic model to assess the long-term
impacts of intervention related changes on HIV incidence
and prevalence. Our model is a dynamic compartment
model focusing on 8 distinct sexual and drug use risk
groups within the community. Cost data are available
from existing intervention analyses. RESULTS: 778 per-
sons were enrolled in the NCCoOp intervention in Wake
and Durham counties, NC. Of these, 80 (11.5%) were
HIV positive. Using data collected prior to intervention,
our model predicts that HIV prevalence will rise to 18%
of the NCCoOp population in five years. The epidemic is
driven predominantly by high-frequency needle users
(HFNU), primary needle users (PNU), and primary crack
users (PCU) who account for 79% of new infections over
this time period. Using data collected after intervention,
our model predicts HIV prevalence will decline to 7% of
the NCCoOp population in five years. However, HFNU,
PNU, and PCU account for 89% of new infections in this
case. Risky drug use and sexual behaviors were dramati-
cally reduced by intervention and this accounts for most
of the reduction in HIV prevalence. Other factors influ-
encing the reduction in HIV prevalence are AIDS mortal-
ity and growth in the drug using population. CONCLU-
